Lifonebart - Business-News-Today.com

🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →

Business news, market intelligence, and global industry analysis.

The Latest

Autonomous excavators and AI-powered construction equipment are moving onto commercial jobsites as contractors test whether operatorless earthmoving can improve productivity, safety and equipment utilisation. Representative image.

Autonomous construction equipment: How AI is moving heavy machinery out of the cab

TikTok and ByteDance’s proposed $400 million US children’s privacy settlement faces a judicial hurdle over termination of a 2019 consent decree. Representative image.

TikTok’s $400m US privacy settlement hits judicial hurdle over 2019 consent decree

CXMT is reportedly preparing a NAND flash research and development production line in Beijing as the newly listed Chinese memory-chip company expands beyond DRAM. Representative image.

CXMT targets NAND flash as $8.6bn IPO gives China’s memory champion room to expand

Morgan Stanley’s North Haven Private Income Fund is working through another oversubscribed repurchase offer as private-credit liquidity demand remains elevated. Representative image.

Morgan Stanley private credit fund again gets withdrawal requests above its 5% limit

Novartis has discontinued VHB937, also known as lifonebart, in amyotrophic lateral sclerosis after a Phase 2 clinical trial failed to meet key efficacy objectives. Representative image.

Read More

Pharma Industry News

Novartis drops ALS drug lifonebart after Phase 2 trial misses key goals

Novartis has discontinued development of VHB937, or lifonebart, in amyotrophic lateral sclerosis after a 251-patient Phase 2 trial missed its primary and secondary objectives, adding to several recent pipeline disappointments.

September 18, 2026

web analytics